European Archives - Page 511 of 1200 - European Medical Journal

Editor's Letter: December 2022

Pharma should double down on its patient centricity efforts to help tackle inequalities in 2023 and beyond, says Helena Beer.

Pharma review of the year 2022

Helena and Isabel are joined by six guests to round off 2022 and Season 3 with a look back at the key highlights of the past 12 months.

EMJ Gastroenterology 11 [Supplement 9] 2022

This poster review article summarised selected original research covering recent advances in the management of various gastrointestinal diseases, including inflammatory bowel disease, disorders of gut–brain interactions, gastro-oesophageal reflux disease, and pancreatic disorders, presented at the United European Gastroenterology (UEG) Week, which took place in Vienna, Austria, between 8th–11th October 2022.

Recent Advances in the Management of Gastrointestinal Disease

Interdisciplinary sessions at the recent United European Gastroenterology (UEG) Week, held in Vienna, Austria, from 8th to 11th October 2022, covered new approaches to the diagnosis and treatment of gastrointestinal and hepatic disorders, with a focus on advances in the non-invasive management of these diseases. Abstract-based and poster sessions presented original research from Europe and other parts of the world.

EMJ Hepatology 10 [Supplement 4] 2022

This symposium took place at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2022, where experts highlighted the importance of communication between healthcare professionals (HCP) and patients with hepatitis B.

Nothing About Me Without Me: Shared Decision-Making in Chronic Hepatitis B

Hepatitis B affects more than 296 million people worldwide, according to the World Health Organization (WHO). More than 1.5 million new infections occur each year, despite the availability of safe and effective vaccines.

Challenging the postcode health lottery

A postcode can determine health outcomes more than genetics. How can pharma help to solve the postcode lottery?

Prevalence of SARS-CoV-2 Cellular and Humoral Immunity Amongst Patients on Dialysis After the First Vaccination Campaign

Global immunisation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the standard-of-care in preventing COVID-19…

Anti-TNF Treatment in Crohn’s Disease Complicated by Intra-abdominal Abscess

Excess production of TNF-α leads to chronic inflammation and tissue damage in immune-mediated inflammatory diseases (IMID) such as Crohn’s Disease (CD), rheumatoid arthritis, and psoriasis. The introduction of anti-TNF agents revolutionised therapy for patients with IMIDs, and two anti-TNFs are currently approved for use in CD in Europe: infliximab and adalimumab.

EMJ Gastroenterology 11 [Supplement 8] 2022

This mini-review is the fourth in a series exploring TNF inhibitors in treating immune-mediated inflammatory disease. Specifically, this mini-review summarises the evidence of anti-TNFs in Crohn’s disease (CD) complicated by intra-abdominal abscess.